Hyqvia FDA Approval History
FDA Approved: Yes (First approved September 12, 2014)
Brand name: Hyqvia
Generic name: immune globulin and hyaluronidase
Dosage form: Solution for Subcutaneous Administration
Company: Takeda Pharmaceutical Company Limited
Treatment for: Primary Immunodeficiency Syndrome, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Hyqvia (immune globulin and hyaluronidase) is an immune globulin with a recombinant human hyaluronidase combination used for the treatment of primary immunodeficiency (PI) and chronic inflammatory demyelinating polyneuropathy (CIDP).
- Hyqvia is indicated for the treatment of:
- Primary Immunodeficiency (PI) in adults and pediatric patients two years of age and older.
- Maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
Development timeline for Hyqvia
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
